header-image

Supply Chain of ATMPs - Live Online Training

7/8 May 2026

Seminar-Nr. 22600

Referent:innen

Dr Andrea Zobel

Dr Andrea Zobel

World Courier

Claudia Angenendt

Claudia Angenendt

Lonza

Carla Kreissig

Carla Kreissig

Cellex

Kati Kebbel

Kati Kebbel

Fraunhofer-Institut für Zelltherapie und Immunologie IZI


Zielgruppe

This event is designed for professionals involved in the development and delivery of advanced therapy medicinal products (ATMPs), including experts in the supply chain and logistics, quality and regulatory affairs, manufacturing and quality control (QC), treatment center staff and project managers from biotech, pharma, and academic institutions working with cell and gene therapies.


Zielsetzung

Advanced Therapy Medicinal Products (ATMPs), including cell and gene therapies, represent a distinct class of medicinal products as defined under Regulation (EC) No 1394/2007 and are subject to specific regulatory, quality, and safety requirements. While these therapies offer significant therapeutic potential, their development and commercialization are associated with a high level of complexity throughout the entire supply chain. From donor collection or patient apheresis to manufacturing, quality control, storage, transport, regulatory release, and bedside administration, ATMPs challenge established pharmaceutical supply chain models.

The individualized nature of many ATMPs, particularly autologous therapies, results in small batch sizes, limited shelf life, and stringent requirements for temperature control, traceability, and segregation. Compliance with Good Manufacturing Practice (GMP), Good Distribution Practice (GDP), and applicable GxP guidelines necessitates strict implementation of chain of identity and chain of condition concepts to ensure product quality, patient safety, and regulatory compliance across all supply chain steps.

This event provides a structured overview of the ATMP supply chain, addressing scientific, technical, regulatory, and operational aspects in accordance with EU and international regulatory frameworks. It covers autologous, allogeneic, and in vivo gene therapies and examines how their specific characteristics influence logistics design, manufacturing strategies, and quality systems. Key topics include storage and transport temperature strategies, cryogenic versus non-cryogenic supply chains, regulatory challenges related to EU importation, Qualified Person (QP) release, dangerous goods classification under ADR/IATA, and the use of digital solutions to support traceability, monitoring, and orchestration.

The objective of this event is to provide participants with a comprehensive understanding of ATMP supply chain requirements and practical solutions. Through expert insights, real world case studies and experience reports from industry and treatment center, attendees will learn how to design scalable, compliant, and patient centric supply chains. The event aims to foster cross functional understanding, support informed decision making and encourage collaboration among stakeholders involved in bringing ATMPs safely and efficiently from vein to vein.


Programm

Introduction and Overview of Cell & Gene Therapies
  • What are ATMPs?
  • Types of ATMPs and their status of today
  • Supply chain of allogeneic, autologous and in vivo gene therapies
  • Specific requirements of the ATMP supply chain
To Freeze or not to Freeze – Storage and Transport Temperatures of Cell Therapies
  • Pros and cons of freezing donations and cell therapies
  • How temperature and primary package impact stability and logistics feasibility
  • Examples and case studies of feasible and not feasible supply chain plans
  • Suggestions for a scalable ATMP supply chain
Regulatory Challenges and Solutions
  • Challenges of the EU ATMP regulations for the global ATMP supply chain
  • How to manage EU import and QP release of ATMPs
  • How to label and serialize investigational and commercial ATMPs
Centralized vs. Decentralized Manufacturing
  • Centralized Manufacturing Model
  • Vision of bed side treatment and steps to get there
  • Pre-Requisites and benefits of decentralized manufacturing
Small Batches in Patient-Specific Production – QC & Stability Testing
  • Sample Chain of Identity and Chain of Condition
  • Trade-offs between cost efficiency and throughput-time
  • Impact of mutual recognition agreements for ATMPs
  • Parallelizing activities for optimized vein-to-vein cycle
Quality Aspects and Challenges of the Supply Chain for IMP ATMP Manufacturing - An Eperience Report of an Academic CDMO
  • Raw materials
    - Quality requirements
    - Dual sourcing
    - Traceability
    - Chain of identity for cell material
    - Supplier qualification
    - (Raw) material management
  • Final product
    - Shipment requirements and examples 
Solutions for the ATMP Supply Chain
  • The cryogenic supply chain – technical solutions and infrastructure requirements
  • How to assure time-critical ATMP shipments arrive safely at the treatment center
  • Digital solutions for orchestration and tracking of cell therapies
Dangerous Goods Classifications in the ATMP Supply Chain
  • What are dangerous goods and which classifications are used for ATMPs?
  • How to apply the classification UN3245 for genetically modified organisms for gene therapies
  • How to apply the classification UN3373 for infectious substances for donations and finished therapies
  • The consequences of a dangerous classification for the ATMP supply chain
Do not X-RAY ATMPs - Required Precaution or Unnecessary Roadblock?
  • Most ATMP’s are labelled with a “do not X-ray” label and should be exempted from X-ray scans at Airports
  • The X-ray exposure of ATMPs during transportation by airfreight
  • The consequences of the exemption of ATMPs from airport security scans
  • Physical and scientific background and solutions
Perspective of Advanced Therapy Treatment Centers Responsible for Apheresis and Administration
  • How does the quality of starting material influence the manufacturing process and final drug product quality?
  • How to optimize starting material quality?
  • How to handle the product bedside?
  • Points to consider for a collection and an application manual


Weitere Informationen

Technical Requirements
We use Webex for our live online training courses and webinars. At https://www.gmp-compliance.org/training/online-training-technical-information you will find all the information you need to participate in our events and you can check if your system meets the necessary requirements to participate. If the installation of browser extensions is not possible due to your rights in the IT system, please contact your IT department. Webex is a standard nowadays and the necessary installation is fast and easy.

Fees (per delegate plus VAT)
ECA Members € 1,890
APIC Members € 1,990
Non-ECA Members € 2,090
EU GMP Inspectorates € 1.045
The conference fee is payable in advance after receipt of invoice

Presentations/Certificate
The presentations will be made available to you prior to the Live Online Training as PDF files. After the event, you will automatically receive your certificate of participation.

Conference language
The official conference language will be English.

Contacts:
Questions regarding content:
Mr Clemens Mundo (Operations Director), +49(0)62 21 84 44 42, mundo@concept-heidelberg.de
Questions regarding organisation:
Mr Ronny Strohwald (Organisation Manager), +49-62 21 84 44 51, strohwald@concept-heidelberg.de

Datum & Uhrzeiten

Thu, 07 May 2026, 09:00 – 15:30 h
Fri, 08 May 2026, 09:00 – 15:00 h
All times mentioned are CEST

Teilnahmegebühr

ECA-Member*: € 1890,-
Non ECA Member*: € 2090,-
EU/GMP Inspectorates*: € 1045,-
APIC Member Discount*: € 1990,-

Alle Preise zzgl. MwSt. Wichtige Hinweise zur Umsatzsteuer.

* auch unkompliziert per Kreditkarte bezahlbar
American Express Visa Mastercard

icon
Aufzeichnung/weitere Termine nicht verfügbar
Aufzeichnung/weitere Termine nicht verfügbar

Haben Sie noch Fragen?

Wir stehen Ihnen für weitere Auskünfte gerne zur Verfügung.
Tel.: +49 6221 84 44 0
E-Mail: info@concept-heidelberg.de

Frau mit Headset

Zurück

Teilnehmerstimmen - das sagen andere über unsere Seminare:

„Flüssiger Vortrag, neue Aspekte wurden kommuniziert.“
Rainer Tryankowski, DRK-Blutspendedienst  Rheinland-Pfalz und Saarland
Webinar GDP Update 2025
März 2025

„Sehr guter Überblick über die aktuellen GDP Themen. Sehr kurzweilig.“
Juliana Dodillet, Pharma Resources GmbH
Webinar GDP Update 2025
März 2025

„Sehr ausführliche Erklärung“
Jacqueline Buckel, UNITAX-Pharmalogistik GmbH
Webinar GDP Update 2025
März 2025

„Sehr gut: praxisorientiert; Präsentation logisch nachvollziehbar“
Gabriele Unger, Astro-Pharma GmbH
Webinar GDP Update 2025
März 2025

„Sehr informativ und umfangreich, aber immer auf den Punkt gebracht“
Jasmine Merz, Peppler GmbH
Webinar GDP Update 2025
März 2025

Wichtiger Hinweis

Sie können jederzeit eine Bestellung aufgeben.

Bitte beachten Sie jedoch, dass wir aufgrund der Feiertage und unserer Betriebsferien vom 23.12.2025 ab 15:00 Uhr bis einschließlich 01.01.2026 keinen Zugang zur Aufzeichnung bereitstellen können.

Der gewünschte Termin sollte daher nach dem 02.01.2026 liegen.

Vielen Dank für Ihr Verständnis und Frohe Festtage.

Das Team von CONCEPT HEIDELBERG